Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Study of Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Next Previous
Trial Profile

A Phase II Clinical Study of Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 24 Oct 2023 Results (n=28) assessing the safety and efficacy of camrelizumab combined with albumin-bound paclitaxel and S-1 in first-line treatment of HER-2-negative advanced gastric/gastroesophageal junction cancer presented at the 48th European Society for Medical Oncology Congress
  • 14 Apr 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
  • 14 Apr 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top